IGI Logo
Toggle Navigation
News
Hindi
Hindi News
Top News
Screeners
Stocks
Stocks Screener
Stock
News
Stock Market Home Page
Stock News
Industry News
Economy News
Stock on the move
Expert Views
Research Reports
Company Result
Comp Info And Fundamentals
Company Profile
Equity
Financial Ratios
Results
Balance Sheet
Profit And Loss
Cash Flow
Share Holding
Derivatives (F&O)
Get Quotes
Market Watch
Top Gainers
Top Losers
Top Traded Quantity
Top Traded Value
Most Active Puts
Derivatives (F&O)
Most Active Calls
Put Call Ratio
Highest In Premium
Daily Settlement Price
FII and DII Statistics
Open Interest: Highest In OI
Open Interest: Lowest In OI
Derivatives (F&O)
Open Interest: Increase in OI Increase in Price
Open Interest: Decline in OI Decrease in Price
Derivative Watch
Derivatives Dashboard
Historical Data
List of Underlyings & Underlying Info
Derivative Watch
Derivatives Dashboard
Market Reports
Top Gainers
Top Losers
Monthly High/Low
52 Week High
52 Week Low
Market Cap Gainers
Market Cap Losers
PE Ratio
>More Market Reports
IPO
News
IPO News
IPO Issue Reports
Commodity
Commodity Market
Commodity Home Page
Commodity News
Commodity Reports
Market Details
Get Quotes
Top Gainers
Top Losers
Top Volume
Top Value
Top Gainers Spot Market
Top Losers Spot Market
High & Low
Commodity Indices
Technical Analysis
Advance Declines
High & Low
Highest In OI
Lowest OI
Increase In Open Interest(%)
Descrease In Open Interest(%)
Currency
News
Currency News
Economy News
Currency Reports
Mutual Fund
News
Mutual Fund Home Page
Mutual Fund News
Mutual Fund Details
Mutual Fund Home Page
Compare Scheme
Scheme Profile
Mutual fund Investment
Mutual Fund Share Holding
Mutual Fund Statistics
Mutual fund Gainers
Mutual fund Losers
Biggest Schemes
Best Performers
Latest Dividend Details
Tools
Multi Scheme Comparison Tool
Dividend Details
Performance Map
Mutual fund Investment
Mutual fund Share Holding
Mutual Fund Search Category Rankings
Widgets
Stock Widgets
Watchlist
Heatmap
Mutual Fund Widgets
Watchlist
Calculators
EMI Calculator
SIP Calculator
SWP Calculator
GST Calculator
FD Calculator
RD Calculator
Wealth
World
Tips
Intraday Tips
Market Outlook
Stock Tips
Commodity Tips
Currency Tips
Reports
Short Term Investment Opportunities
Long Term Investment Opportunities
Sector Analysis
Commodity Reports
Currency Reports
Mutual Fund Analysis
Podcast
Videos
Videos Category
Business Videos
Budget Videos
News And Politics
Entertainment Videos
Sports Videos
Lifestyle And Fashion Videos
Global News Videos
Calculators
EMI Calculator
SIP Calculator
SWP Calculator
GST Calculator
FD Calculator
RD Calculator
More
Budget 2024
Astrology
Women
Politics
Entertainment
Car&Bike
Gadgets
Lifestyle
Sports
Health
Fashion
Diwali Reports
Diwali Expert Reports
News
Astrology
Beyond Market Car
Beyond Market Entertainment
Beyond Market Fashion
Beyond Market Gadgets
Beyond Market Health
Beyond Market India
Beyond Market Life Style
Beyond Market Sports
Broking Firm Views
Broking Firm Views - Long Term Report
Broking Firm Views - Sector Report
Broking Firm Views - Short Term Report
Budget 2024 Sector Reports
Budget Bites
Budget Economic Servey
Budget Expert Views
Budget Industry
Budget News
Budget Wishlist
Commodities
Commodities Reports
Commodity Top News
Company News
Company Result
Currency News
Currency Report
Currency Top News
Diwali Expert Views
Diwali Market Outlook
Diwali Report
Diwali Technical Report
Economy News
Expert View Institution
Expert Views
Industry News
IPO Analysis
IPO More News
IPO Reports
IPO Top News
Market Outlook
Mutual Fund Analysis
Mutual Fund Expert Views
Mutual Fund More News
Mutual Fund Top News
Podcast - Market Ki Awaaz
Special Event Expert Views
Special Event Reports
Startup
Startup Expections
Startup Speak
Stock Market
Stock On The Move
Top News
Top Stories
Videos
Videos Business
Videos Entertainment
Videos Global News
Videos Lifestyle And Fashion
Videos News And Politics
Videos Sports
Wealth
Women
World Market More News
World Top News
Search
Radiopharma on a gradual recovery path Import alert slows growth prospects in the Generic segment * JP delivered in line earnings, despite a better than expected revenue in 1QFY22. The COVID-related business led to a strong YoY revenue growth. However, reduced number of lung procedures in the Radiopharma segment, increased price erosion in the Sartans portfolio, and price erosion in the base portfolio in the Generics segment led to lower-than-expected profitability, offsetting benefits ...
Buy Jubilant Pharmova Ltd For Target Rs.830 - Motilal Oswal
Import alert on Roorkee facility Jubilant Pharmova (Jubilant) announced that it has received import alert from USFDA for its Roorkee facility. USFDA re-inspected the plant in Mar’21 and subsequently has issued an import alert to it. It is a solid dosage formulations manufacturing facility with supplies to US in addition to ROW markets. USFDA has exempted certain products from purview of import alert subject to fulfilment of certain conditions by the company. We view this developme...
Hold Jubilant Pharmova Ltd For Target Rs.725 - ICICI Securities
Big miss; recovery delayed Jubilant Pharmova’s (Jubilant) Q4FY21 performance was below our estimates with miss of 12/25/21% in revenue/EBITDA/PAT. The Life Science Ingredients business got demerged into Jubilant Ingrevia Ltd from Feb’21. Pharma business revenue grew remained flat at Rs15.8bn, EBITDA margin dropped 420bps YoY to 23.7% and adj. PAT declined 13.7% to Rs1.8bn. The CDMO business benefited from the manufacturing of potential COVID-19 drug and vaccines which contri...
Hold Jubilant Pharmova Ltd For Target Rs.798 - ICICI Securities
Demand prospects favorable; execution remains the key * Jubilant Pharmova (JP) hosted an investor/analyst meet to discuss the business and strategic initiatives in key business segments. * With the COVID disruption behind in key markets, JP expects radiopharma sales to recover in 2HFY22, supplemented by incremental sales from Ruby-Fill in Europe. * JP is proactively undertaking expansions at Montreal and Spokane to be able to cater to future demand in the Contract Development and Ma...
Buy Jubilant Pharmova Ltd For Target Rs.960 - Motilal Oswal
Radiopharma business recovery – key for better outlook CDMO prospects remain promising * Jubilant Pharmova (JP) delivered lower-than-expected 4QFY21 earnings, weighed by muted performances in the Specialty Pharma and Generics segments. Particularly, the Radiopharma segment was adversely affected by lower procedures on account of COVID-19 and increased competition. * We reduce our EPS estimate by 5%/4% for FY22/FY23, reflecting a) a slower uptick in the Radiopharma business, b)...
Buy Jubilant Life Sciences Ltd For Target Rs.960 - Motilal Oswal
Big miss; recovery delayed Jubilant Pharmova’s (Jubilant) Q4FY21 performance was below our estimates with miss of 12/25/21% in revenue/EBITDA/PAT. The Life Science Ingredients business got demerged into Jubilant Ingrevia Ltd from Feb’21. Pharma business revenue grew remained flat at Rs15.8bn, EBITDA margin dropped 420bps YoY to 23.7% and adj. PAT declined 13.7% to Rs1.8bn. The CDMO business benefited from the manufacturing of potential COVID-19 drug and vaccines which contri...
Hold Jubilant Life Sciences Ltd For Target Rs.798 - ICICI Securities
CMO outlook bright; Radiopharma in gradual recovery mode All segments showing strong growth * Jubilant Life Sciences (JLS) delivered higher-than-expected 3QFY21 earnings, led by better traction in a) the Contract Manufacturing Organization (CMO) / Generics category of the Pharma segment and b) Nutritional products in the Life Science Ingredient (LSI) business. * Post the demerger of LSI with Jubilant Ingrevia from 1st Feb’21, the segment is classified as ‘discontinued opera...
Buy Jubilant Life Sciences Ltd For Target Rs.1,120 - Motilal Oswal
Buy Jubilant Life Sciences Ltd For Target Rs. 1,120 CMO outlook bright; Radiopharma in gradual recovery mode All segments showing strong growth * Jubilant Life Sciences (JLS) delivered higher-than-expected 3QFY21 earnings, led by better traction in a) the Contract Manufacturing Organization (CMO) / Generics category of the Pharma segment and b) Nutritional products in the Life Science Ingredient (LSI) business. * Post the demerger of LSI with Jubilant Ingrevia from 1st Feb’...
Jubilant Life Sciences Ltd : CMO outlook bright; Radiopharma in gradual recovery mode By Motilal Oswal
Demerger may complete in FY21 Jubilant Life Sciences (JLS) has recently received the NCLT approval for demerger of pharma and LSI businesses into two separate companies. We believe separate listing of both companies should happen in the next few weeks, before FY21 ends. The company had announced this demerger in Oct’19 with the rationale of two separate and focused entities for pharma & LSI segment and to unlock shareholder value. There could be some value unlocking as combined ...
Add Jubilant Life Sciences Ltd For Target Rs.936 - ICICI Securities
Load More
